SPYGLASS PHARMA INC SHS (SGP)
Health Care · Clinical-stage drug delivery biotech / ophthalmology · NASDAQ
Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
What SPYGLASS PHARMA INC SHS does
Spyglass Pharma is a clinical-stage biopharmaceutical company focused on developing proprietary drug delivery systems for eye diseases. Its lead product candidate is the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which is designed to provide sustained release of medication in conjunction with cataract surgery. The company currently has no products approved for commercial sale.
Themes: ophthalmology, drug delivery systems, cataract surgery, sustained-release therapeutics
Fundamentals
- Price$26.51 as of 2026-08-21 close
- Market cap$887M as of 2026-08-21
- P/En/a earnings data not available
- ROE-75.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.23 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How SGP compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SPYGLASS PHARMA INC SHS looks technically
SPYGLASS PHARMA INC SHS (SGP): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.69 | $21.69 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 42 calendar days ago — the swings before that are what the structure reading is measured on | 42 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 22.8. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with buyers in control | 47.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 65.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($22.50 to $27.82) — its "stochastic" reading is 75 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 75.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 43 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $32.44 | $32.44 |
|---|---|---|
| From the 52-week high | it is 18.3% below its 52-week high (its highest price of the past year) | -18.3% |
| Above the 52-week low | it is 55.4% above its 52-week low (its lowest price of the past year) | +55.4% |
| Below the 52-week high | it is 18.3% below its highest point of the past year | 18.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $32.44 (set on 2026-02-06) | $32.44 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 18.3% below its all-time high | -18.3% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $17.06 (set on 2026-06-17) | $17.06 |
| Above the all-time low | it is 55.4% above its all-time low | +55.4% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 69th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.46 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.46 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $20.88 and $27.96 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $20.88 – $24.42 – $27.96 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.54× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.2% since the prior reading | -2.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.17 toward sell |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.2% |
|---|---|---|
| Gap filled | a 3.3% gap up opened on 2026-08-14 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 28.5 percentage points (the stock gained 30.8% while the market gained 2.3%) | +28.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 17.1 percentage points (the stock gained 20.2% while the market gained 3.1%) | +17.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.6 percentage points (the stock lost 9.6% while the market gained 11.1%) | -20.6% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 4 of the 7 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 7 |
|---|---|---|
| Bearish technical signals | 1 of the 7 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 23% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.2% of the share price. | +23.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid since 2026-02-06, so the typical buyer over that stretch is showing a gain. That average is $23.71 — a volume-weighted average of daily closes over 126 sessions, not a true tick-by-tick VWAP. | +11.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $25.76 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +2.9% |
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $22.80.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $21.89 and $22.80 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-12, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently CUT · Printed a doji candle · Trading above the Ichimoku cloud · Elliott wave 4 pullbacks | Learn: adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$44.00 range $37.00 – $62.00; median $42.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SGP
- Consensus EPS estimate-$0.6212 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial dependence on the success of the BIM-IOL System, which is still in clinical trials.","History of significant operating losses and no commercial revenue, with a need for substantial additional capital to fund future operations.","Risks associated with the regulatory approval process and potential for failure to demonstrate safety and efficacy in clinical trials."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Cluster buying: 11 different insiders reported open-market purchases (SEC code P) of SGP within a 30-day window between 2026-02-09 and 2026-02-09. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-02-09. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SGP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
2 institutional 13F filers reported holding SGP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 2
- Reported shares held 161,989
- Reported value $4,197,135
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SGP had 1,140,494 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SGP had 3.41% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.06 days to cover at the same settlement.
- Reported short interest (shares) 1,140,494
- Short interest (% of shares outstanding) 3.41%
- Prior settlement (shares) 1,130,776
- Reported change 0.86%
- Days to cover (reported) 12.06
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Allergan (ABBV)
- Alcon (ALC)
- Bausch + Lomb (BLCO)
- Glaukos (GKOS)
- EyePoint Pharmaceuticals (EYPT)
- Ocular Therapeutix (OCUL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SGP vs…
Frequently asked questions
What does SPYGLASS PHARMA INC SHS (SGP) do?
Spyglass Pharma is a clinical-stage biopharmaceutical company focused on developing proprietary drug delivery systems for eye diseases. Its lead product candidate is the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which is designed to provide sustained release of medication in conjunction with cataract surgery. The company currently has no products approved for commercial sale.
What sector is SPYGLASS PHARMA INC SHS (SGP) in?
SPYGLASS PHARMA INC SHS (SGP) is classified in the Health Care sector. Its industry is Clinical-stage drug delivery biotech / ophthalmology. It trades on NASDAQ.
Who are SPYGLASS PHARMA INC SHS's (SGP) competitors?
Notable peers of SPYGLASS PHARMA INC SHS (SGP) include Allergan, Alcon, Bausch + Lomb, Glaukos and EyePoint Pharmaceuticals. This peer set is informational only — not financial advice.
Is SPYGLASS PHARMA INC SHS (SGP) overbought or oversold right now?
SPYGLASS PHARMA INC SHS (SGP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SGP come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.